Paclical micellular paclitaxel: Completed Phase III enrollment

Oasmia completed enrollment of 650 patients in an open-label, European Phase III trial comparing 250 mg/m 2 Paclical given as a 1-hour infusion plus carboplatin on day 1 of each 21-day cycle vs. paclitaxel plus carboplatin. The trial enrolled patients with recurrent epithelial cancer, primary peritoneal cancer or fallopian tube cancer. ...